Tumor regression by combination antisense therapy against Plk1 and Bcl-2

Oncogene

Volumn 22, Issue 1, 2003, Pages 69-80

  Elez, Robert ^a,c   Piiper, Albrecht ^a,c   Kronenberger, Bernd ^a,c   Kock, Martin ^b   Brendel, Martin ^a   Hermann, Eva ^a,c   Pliquett, Uwe ^d   Neumann, Eberhardt ^d   Zeuzem, Stefan ^a,c  

^a GOETHE UNIVERSITY   (Germany)

^b GOETHE UNIVERSITY MEDICAL SCHOOL   (Germany)

^c SAARLAND UNIVERSITY   (Germany)

^d NONE

Author keywords

Antisense therapy; BCL 2; Cell cycle; Electroporation; Mitotic catastrophe; Polo like kinase 1 (PLK1)

Indexed keywords

ANTISENSE OLIGODEOXYNUCLEOTIDE; CELL PROTEIN; JWG 100; JWG 110; JWG 160; JWG 2000; JWG 340; JWG 370; JWG 90; OBLIMERSEN; OLIGODEOXYNUCLEOTIDE PHOSPHOROTHIOATE; POLO LIKE KINASE 1; PROTEIN BCL 2; UNCLASSIFIED DRUG;

ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER THERAPY; CELL CYCLE; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; ELECTROPORATION; GENE EXPRESSION; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; NORTHERN BLOTTING; NUDE MOUSE; PRIORITY JOURNAL; TUMOR REGRESSION; TUMOR VOLUME; TUMOR XENOGRAFT; WESTERN BLOTTING;

ANIMALS; BASE SEQUENCE; CELL CYCLE PROTEINS; DOWN-REGULATION; ELECTROPORATION; HUMANS; MICE; MICE, NUDE; MICROSCOPY, FLUORESCENCE; NEOPLASM TRANSPLANTATION; NEOPLASMS; OLIGONUCLEOTIDES, ANTISENSE; PROTEIN KINASES; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; THIONUCLEOTIDES; TUMOR CELLS, CULTURED;

ANIMALIA; MUS MUSCULUS;

EID: 0037427082     PISSN: 09509232     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.onc.1206038     Document Type: Article

References (47)

1. Agrawal S, Temsamani J and Tang JY. (1991). Pharmacokinetics, biodistribution, and stability of oligodeoxynucleotide phosphorothioates in mice. Proc. Natl. Acad. Sci. USA, 88, 7595-7599.
2. Antonsson B, Conti F, Ciavatta A, Montessuit S, Lewis S, Martinou I, Bernasconi L, Bernard A, Mermod JJ, Mazzei G et al. (1997). Inhibition of Bax channel-forming activity by BCL-2. Science, 277, 370-372.
3. Chan TA, Hermeking H, Lengauer C, Kinzler KW and Vogelstein B. (1999). 14-3-3 Sigma is required to prevent mitotic catastrophe after DNA damage. Nature, 401, 616-620.
4. Cogswell JP, Brown CE, Bisi JE and Neill SD. (2000). Dominant-negative polo-like kinase 1 induces mitotic catastrophe independent of cdc25C function. Cell Growth Diff., 11, 615-623.
5. Crooke ST and Lebleu B. (eds). (1993). Antisense Research and Applications. CRC Press: Boca Raton, FL.
6. Donaldson MM, Tavares AA, Hagan IM, Nigg EA and Glover DM. (2001). The mitotic roles of polo-like kinase. J. Cell Sci., 114, 2357-2358.
7. Draghia-Akli R, Fiorotto ML, Hill LA, Malone PB, Deaver DR and Schwartz RJ. (1999). Myogenic expression of an injectable protease-resistant growth hormone-releasing hormone augments long-term growth in pigs. Nat. Biotechnol., 17, 1179-1183.
8. Elez R, Piiper A, Giannini CD, Brendel M and Zeuzem S. (2000). Polo-like kinase 1, a new target for antisense tumor therapy. Biochem. Biophys. Res. Commun., 269, 352-356.
9. Golsteyn RM, Schultz SJ, Bartek J, Ziemiecki A, Ried T and Nigg EA. (1994). Cell cycle analysis and chromosomal localization of human PLK1 a putative homologue of the mitotic kinases Drosophila polo and Saccharomyces cerevisiae Cdc5. J. Cell Sci., 107, 1509-1517.
10. Grover R and Wilson GD. (1996). BCL-2 expression in malignant melanoma and its prognostic significance. Eur. J. Surg. Oncol., 22, 347-349.
11. Hamanaka R, Maloid S, Smith MR, O'Connell CD, Longo DL and Ferris DK. (1994). Cloning and characterization of human and murine homologues of the Drosophila polo serine-threonine kinase. Cell Growth Differ., 5, 249-257.
12. Heller R, Jaroszeski MJ, Glass LF, Messina JL, Rapaport DP, DeConti RC, Fenske NA, Gilbert RA, Mir LM and Reintgen DS. (1996). Phase I/II trial for the treatment of cutaneous and subcutaneous tumors using electrochemotherapy. Cancer, 77, 964-971.
13. Heller R, Jaroszeski MJ, Reintgen DS, Puleo CA, DeConti RC, Gilbert RA and Glass LF. (1998). Treatment of cutaneous and subcutaneous tumors with electrochemotherapy using intralesional bleomycin. Cancer, 88, 148-157.
14. Henry SP, Novotny W, Leeds J, Auletta C and Kornbrust DJ. (1997). Inhibition of coagulation by a phosphorothioate oligonucleotide. Antisense Nucleic Acid Drug Dev., 7, 503-510.
15. Holtrich U, Wolf G, Brauninger A, Karn T, Bohme B, Rubsamen-Waigmann H and Strebhardt K. (1994). Induction and down-regulation of PLK, a human serine/threonine kinase expressed in proliferating cells and tumors. Proc. Natl. Acad. Sci., USA 91, 1736-1740.
16. Jansen B, Schlagbauer-Wadl H, Brown BD, Bryan RN, Elsas A, Muller M, Wolf L, Eichler HG and Pehamberger H. (1998). BCL-2 antisense therapy chemosensitizes human melanoma in SCID mice. Nat. Med., 4, 232-234.
17. Jansen B, Wacheck V, Heere-Ress E, Schlagbauer-Wadl H, Hoeller C, Lucas T, Hoermann M, Hollenstein U, Wolff K and Pehamberger H. (2000). Chemosensitisation of malignant melanoma by BCL2 antisense therapy. Lancet, 356, 1728-1733.
18. Khaled Z, Benimetskaya L, Zeltser R, Khan T, Sharma HW, Narayanan R and Stein CA. (1996). Multiple mechanisms may contribute to the cellular anti-adhesive effects of phosphorothioate oligodeoxynucleotides. Nucleic Acids Res., 24, 737-745.
19. Knecht R, Elez R, Oechler M, Solbach C, von Ilberg C and Strebhardt K. (1999). Prognostic significance of polo-like kinase (PLK) expression in squamous cell carcinomas of the head and neck. Cancer Res., 59, 2794-2797.
20. Kotani S, Tugendreich S, Fujii M, Jorgensen PM, Watanabe N, Hoog C, Hieter P and Todokoro K. (1998). PKA and MPF-activated polo-like kinase regulate anaphase-promoting complex activity and mitosis progression. Mol. Cell, 3, 371-380.
21. Lake RJ and Jelinek WR. (1993). Cell cycle- and terminal differentiation-associated regulation of the mouse mRNA encoding a conserved mitotic protein kinase. Mol. Cell Biol., 13, 7793-7801.
22. Lane HA and Nigg EA. (1996). Antibody microinjection reveals an essential role for human polo-like kinase 1 (PLK1) in the functional maturation of mitotic centrosomes. J. Cell Biol., 135, 1701-1713.
23. Lee SE, Frenz LM, Wells NJ, Johnson AL and Johnston LH. (2001). Order of function of the budding-yeast mitotic exit-network proteins Teml, Cdc15, Mobl, Dbf2, and Cdc5. Curr. Biol., 11, 784-788.
24. Liotta L and Petricoin E. (2000). Molecular profiling of human cancer. Nat. Rev. Genet., 1, 48-56.
25. Minn AJ, Velez P, Schendel SL, Liang H, Muchmore SW, Fesik SW, Fill M and Thompson CB. (1997). Bcl-x(L) forms an ion channel in synthetic lipid membranes. Nature, 385, 353-357.
26. Mir LM, Belehradek M, Domenge C, Orlowski S, Poddevin B, Belehradek J Jr, Schwaab G, Luboinski B and Paoletti C. (1991). Electrochemotherapy, a new antitumor treatment: first clinical trial. C. R. Acad. Sci., 313, 613-618.
27. Mir LM and Reintgen DS. (1996). Phase I/II trial for the treatment of cutaneous and subcutaneous tumors using electrochemotherapy. Cancer, 77, 964-971.
28. Monia BP, Johnston JF, Geiger T, Muller M and Fabbro D. (1997). Antitumor activity of a phosphorothioate antisense oligodeoxynucleotide targeted against C-raf kinase. Nat. Med., 2, 668-675.
29. Neumann E, Kakorin S and Toensing K. (1999). Fundamentals of electroporative delivery of drugs and genes. Bioelectrochem. Bioenerg., 48, 3-16.
30. Neumann E, Kakorin S and Toensing K. (2000). Principles of membrane electroporation and transport of macromolecules. In: Jarosteki M J, Heller R, Gilbert R. (eds). Methods in Molecular Medicine, Vol. 37, Humana Press: Totowa, NJ, pp 1-35.
31. Neumann E, Schaefer-Ridder M, Wang Y and Hofschneider PH. (1982). Gene transfer into mouse lyoma cells by electroporation in high electric fields. EMBO J., 7, 841-845.
32. Ramchandani S, MacLeod AR, Pinard M, von Hofe E and Szyf M. (1997). Inhibition of tumorigenesis by a cytosine-DNA, methyltransferase, antisense oligodeoxynucleotide. Proc. Natl. Acad. Sci. USA. 9, 684-689.
33. Reed JC. (1995). Regulation of apoptosis by BCL-2 family proteins and its role in cancer and chemoresistance. Curr. Opin. Oncol., 7, 541-546.
34. Sambrook J, Fritsch EF and Maniatis T. (1989). Molecular Cloning: A Laboratory Manual. Cold Spring Harbor Lab. Press: Plainview, NY.
35. Sanchez Y, Bachant J, Wang H, Hu F, Liu D, Tetzlaff M and Elledge SJ. (1999). Control of the DNA damage checkpoint by chkl and rad53 protein kinases through distinct mechanisms. Science. 285, 1166-1171.
36. Sheehan JP and Lan HC. (1998). Phosphorothioate oligonucleotides inhibit the intrinsic tenase complex. Blood 92, 1617-1625.
37. Smith MR, Wilson ML, Hamanaka R, Chase D, Kung H, Longo DL and Ferris DK. (1997). Malignant transformation of mammalian cells initiated by constitutive expression of the polo-like kinase. Biochem. Biophys. Res. Commun., 234, 397-405.
38. Smits VA, Klompmaker R, Arnaud L, Rijksen G, Nigg EA and Medema RH. (2000). Polo-like kinase-1 is a target of the DNA damage checkpoint. Nat. Cell Biol., 2, 672-676.
39. Stein CA. (1995). Does antisense exist? Nat. Med., 1, 1119-1121.
40. Swanson PE, Carroll SB, Zhang XF and Mackey MA. (1995). Spontaneous premature chromosome condensation, micronucleus formation, and non-apoptotic cell death in heated HeLa S3 cells. Ultrastructural observations. Am. J. Pathol., 146, 963-971.
41. Toyoshima-Morimoto F, Taniguchi E, Shinya N, Iwamatsu A and Nishida E. (2001). Polo-like kinase 1 phosphorylates cyclin B1 and targets it to the nucleus during prophase. Nature, 410, 215-220.
42. van Vugt MA, Smits VA, Klompmaker R and Medema RH. (2001). Inhibition of polo-like kinase-1 by DNA damage occurs in an ATM-/ATR-dependent fashion. J. Biol. Chem., 276, 41656-41660.
43. Wagner RW and Flanagan WM. (1997). Antisense technology and prospects for therapy of viral infections and cancer. Mol. Med. Today, 3, 31-38.
44. Wang H, Cai Q, Zeng X, Yu D, Agrawal S and Zhang R. (1999). Antitumor activity and pharmacokinetics of a mixed-backbone antisense oligonucleotide targeted to the RI alpha subunit of protein kinase A after oral administration. Proc. Natl. Acad. Sci. USA, 96, 13989-13994.
45. Wang Y and Becker D. (1997). Antisense targeting of basic fibroblast growth factor and fibroblast growth factor receptor-1 in human melanomas blocks intratumoral angiogenesis and tumor growth. Natl. Med., 3, 887-893.
46. Webb A, Cunningham D, Cotter F, Clarke PA, di Stefano F, Ross P, Corbo M and Dziewanowska Z. (1997). BCL-2 antisense therapy in patients with non-Hodgkin lymphoma. Lancet, 349, 1137-1141.
47. Wolf G, Elez R, Doermer A, Holtrich U, Ackermann H, Stutte HJ, Altmannsberger HM, Rubsamen-Waigmann H and Strebhardt K. (1997). Prognostic significance of polo-like kinase (PLK) expression in non-small cell lung cancer. Oncogene, 14, 543-549.